Compare CORT & OSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | OSK |
|---|---|---|
| Founded | 1998 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.4B |
| IPO Year | 2001 | 2009 |
| Metric | CORT | OSK |
|---|---|---|
| Price | $113.05 | $147.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $96.50 | ★ $166.79 |
| AVG Volume (30 Days) | ★ 805.4K | 573.4K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 1.14 |
| Revenue | $761,407,000.00 | ★ $7,705,500,000.00 |
| Revenue This Year | $26.08 | $5.94 |
| Revenue Next Year | $26.98 | $7.19 |
| P/E Ratio | $1,259.44 | ★ $135.18 |
| Revenue Growth | 12.79 | ★ 12.83 |
| 52 Week Low | $28.66 | $116.77 |
| 52 Week High | $126.38 | $180.49 |
| Indicator | CORT | OSK |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 43.07 |
| Support Level | $77.73 | $146.50 |
| Resistance Level | $122.21 | $158.91 |
| Average True Range (ATR) | 4.04 | 4.76 |
| MACD | -1.68 | -0.71 |
| Stochastic Oscillator | 15.22 | 4.24 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.